Abstract
During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Current HIV Research
Title:β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin
Volume: 10 Issue: 4
Author(s): Fabien P. Blanchet, J. P. Mitchell and Vincent Piguet
Affiliation:
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Abstract: During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Export Options
About this article
Cite this article as:
P. Blanchet Fabien, P. Mitchell J. and Piguet Vincent, β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792441
DOI https://dx.doi.org/10.2174/157016212800792441 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets siRNA Modifications and Sub-Cellular Localization: A Question of Intracellular Transport?
Current Pharmaceutical Design E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Reverse Pharmacognosy: Another Way to Harness the Generosity of Nature
Current Pharmaceutical Design Changes in Gene Expression in the Rat Hippocampus Following Exposure to 56Fe Particles and Protection by Berry Diets
Central Nervous System Agents in Medicinal Chemistry The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate
Letters in Drug Design & Discovery Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Modular Organization in a Cell: Concepts and Applications
Current Bioinformatics Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression
Current Signal Transduction Therapy